Biogen Expects Confirmatory Aduhelm Data In 2026, But Is It Too Late?
Data on rivals will be available well before
Executive Summary
Biogen's update on the timeline for running a confirmatory study of the Alzheimer's treatment is faster than the nine years required by FDA under the accelerated approval.
You may also be interested in...
Lilly’s Alzheimer’s Drug Will Get ‘Easier Ride’ Than Aduhelm But Does Not Show Clinical Benefit, Prof Says
Harsh assessment of Lilly’s Phase II study by UCL and UCSF professors suggests donanemab may face same hurdles as Biogen’s Aduhelm. Lilly exec says the drug slowed disease progression by six months, but UCL prof says that won’t make a difference.
The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
Biogen’s Q3 Aduhelm Sales Even Worse Than Expected
Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.